title: Analysis of background factors influencing long-term prognosis of patients with chronic hepatitis C treated with interferon.
abstract: OBJECTIVE
  Interferon (IFN) therapy has been used as antiviral therapy for chronic hepatitis C (CH-C); however, complete response to the therapy is observed in only about 30% of patients in Japan. Background factors involved in the responsiveness to IFN therapy, and progression to liver cirrhosis (LC) and hepatocellular carcinoma (HCC) after IFN therapy have not yet been sufficiently investigated.
  
  
  METHODS
  One hundred twenty-one patients with CH-C who received IFN therapy at Showa University Hospital between 1984 and 1999 were analyzed.
  
  
  RESULTS
  At 6 months after the termination of IFN therapy, 53 patients achieved a complete response, 11 patients incomplete response, and 57 patients no response. During a mean follow-up of 52.7 months, 12 patients progressed to LC, and 10 patients developed HCC. Multivariate analysis showed that significant independent factors involved in progression to LC were platelet count and the efficacy of IFN therapy. The significant independent factor involved in the development of HCC was platelet count. The factor involved in the therapeutic effect at 6 months after the termination of IFN administration was the serum hepatitis C virus (HCV) RNA levels before IFN therapy.
  
  
  CONCLUSIONS
  Patients with high HCV RNA levels and low platelet counts should be considered to be at high risk of progressing to LC and developing of HCC and should be carefully followed after IFN therapy using ultrasonography, CT scan and MRI.
authors.affiliation: Showa University Health Service Center, Showa University School of Pharmaceutical Sciences, Tokyo, Japan. yoneyama@med.showa-u.ac.jp
authors.forename: Keiichiro
authors.initials: K
authors.lastname: Yoneyama
authors.forename: Mayumi
authors.initials: M
authors.lastname: Yamaguchi
authors.forename: Yuji
authors.initials: Y
authors.lastname: Kiuchi
authors.forename: Toshio
authors.initials: T
authors.lastname: Morizane
authors.forename: Minoru
authors.initials: M
authors.lastname: Shibata
authors.forename: Keiji
authors.initials: K
authors.lastname: Mitamura
mesh_terms: D000328:Adult; D000368:Aged; D000998:Antiviral Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000175:diagnosis*; D015331:Cohort Studies; D005260:Female; D016174:Hepacivirus / Q000235:genetics / Q000502:physiology; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D016898:Interferon-alpha / Q000008:administration & dosage / Q000627:therapeutic use*; D016899:Interferon-beta / Q000008:administration & dosage / Q000627:therapeutic use*; D008103:Liver Cirrhosis / Q000175:diagnosis*; D008113:Liver Neoplasms / Q000175:diagnosis; D008297:Male; D008875:Middle Aged; D010976:Platelet Count; D011379:Prognosis; D012367:RNA, Viral / Q000097:blood; D012189:Retrospective Studies; D012307:Risk Factors; D016896:Treatment Outcome
chemical_list: D000998:Antiviral Agents; D016898:Interferon-alpha; D012367:RNA, Viral; D016899:Interferon-beta